Tourette's syndrome is named after the French doctor, Georges Gilles de la Tourette, who first described the syndrome and its symptoms in the 19th century. There's no cure for Tourette's syndrome, but ...

Practitioner Review: Treatments for Tourette syndrome in children and young people - a systematic review. Journal of child psychology and psychiatry, and allied disciplines, 57 (9), 988–1004 ...

Tourette syndrome (TS) often begins in childhood, but for many patients, its challenges and care needs continue into adulthood. From early recognition and behavioral interventions to managing ...

It made seven recommendations to the industries to improve the treatment and management of Tourette syndrome. The PM used a Tourette slur. Advocates say it'll have real-life impacts ...

Melissa Licari said Australians living with Tourette syndrome face ongoing challenges, including long waits for diagnosis, limited access to treatment, stigma and discrimination. Source: Supplied ...

The first line treatment option will remain as psychoeducation, which combines the elements of cognitive-behaviour therapy and education, before the technology could be offered. It is estimated that ...

Scientists have found a possible cause of Tourette’s syndrome in a discovery which could “lay the foundation for a new generation of treatments’”. More than 300,000 people are thought to ...

A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition.

John Krystal, MD, Editor of Biological Psychiatry, says, "Current treatments for Tourette syndrome do not address the underlying causes of the condition.

The phase 3 D1AMOND trial (ClinicalTrials.gov Identifier: NCT05615220) evaluated the safety, tolerability, and efficacy of ecopipam in pediatric and adult participants with Tourette syndrome.

In a large, multinational Phase 3 study, 167 pediatric subjects and 49 adult subjects with Tourette syndrome received ecopipam in a 12-week open-label test.